Testing On Tissues and Cells Sector Reaches USD 7.5 Billion

Kalorama's report, “The World Market for Tissue Diagnostics and Cell-Based Diagnostics,” covers testing in histology and cytology, in situ hybridization (ISH), HPV tests, flow cytometry, digital pathology and image cytometry, hematology cell assays, immunohistochemistry, CTC, and others.

"Growth in the tissue and cell diagnostics market is being driven by research to better understand the biological mechanisms and processes of cancer," said Bruce Carlson, publisher of Kalorama information, "Biopsy samples are the most common and effective in this area." Tissue and cell-based testing technologies currently being used in clinical laboratories, plus emerging technologies, are being studied by life science researchers in addition to their studies to better understand the roles of proteins and other molecules. Cell-based assays are also central in drug discovery and development (basic research, preclinical toxicology, and other).

Growth is also driven by development of new targeted therapies based on research outcomes, according to Kalorama’s report. In cancer, the Pharmaceutical Research and Manufacturers of America (PhRMA) estimated that nearly 800 new medicines and vaccines are in clinical testing for cancer. While these new therapies represent a wide range of different approaches, they include new targeted therapies. In March 2014, IMS Health reported that 22 new oncology therapies were launched in the previous two years. The American Cancer Society had predicted 1,665,540 newly diagnosed cancer cases for 2014.

The Kalorama report includes market-trends and breakouts of important segments, as well as profiling scores of companies and providing geographic breakdowns of this market.

Related Links:
Kalorama Information
World Market for Tissue Diagnostics and Cell-Based Diagnostics